相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
CD40 Agonist Antibodies in Cancer Immunotherapy
Robert H. Vonderheide
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
On the mechanism of anti-CD39 immune checkpoint therapy
David Allard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Oncolytic Viruses and the Immune System: The Dynamic Duo
Ana Lemos de Matos et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Can Personalized Neoantigens Raise the T Cell Bar?
Neeha Zaidi
CELL (2020)
Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial
A. McArthur et al.
CANCER RESEARCH (2020)
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
Cinzia Solinas et al.
ESMO OPEN (2020)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv192, 2018)
D. Planchard et al.
ANNALS OF ONCOLOGY (2019)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Neoepitopes-based vaccines: challenges and perspectives
Vincent Alcazer et al.
EUROPEAN JOURNAL OF CANCER (2019)
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Tori N. Yamamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
NKTR-214+nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
Arlene O. Siefker-Radtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker et al.
LANCET ONCOLOGY (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics
Karen Autio et al.
CURRENT ONCOLOGY REPORTS (2019)
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
Michael E. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy.
Mohammed M. Milhem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CA045-001: A phase Ill, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
Nikhil I. Khushalani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Asim Amin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot et al.
CELL RESEARCH (2019)
Integration of radiotherapy and immunotherapy for treatment of oligometastases
Sean P. Pitroda et al.
LANCET ONCOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Radioimmunotherapy for the treatment of head and neck cancer
Sara D. Karam et al.
LANCET ONCOLOGY (2019)
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Fernando G. Herrera et al.
LANCET ONCOLOGY (2019)
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
Eric Deutsch et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
OX40 (CD 134) and OX40 ligand, important immune checkpoints in cancer
Juan Deng et al.
ONCOTARGETS AND THERAPY (2019)
812PSTING agonist, ADU-S100, yields potent anti-tumour activity and therapeutically favorable immune profile in an esophageal adenocarcinoma model
A H Zaidi et al.
ANNALS OF ONCOLOGY (2019)
LBA70Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial
J A Chesney et al.
ANNALS OF ONCOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC
Marion Humbert et al.
CANCER RESEARCH (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
Phase I study of E7046, a novel PGE(2) receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
Robert M. Jotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
Anti-Angiogenics: Current Situation and Future Perspectives
Katja Zirlik et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Immunological effects of BRAF plus MEK inhibition
Paolo A. Ascierto et al.
ONCOIMMUNOLOGY (2018)
ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy
Oliviero Marinelli et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2018)
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011+/- nivolumab (nivo) in patients (pts) with advanced cancers.
Timothy Anthony Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
Juneko E. Grilley-Olson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings
Takami Sato et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
IMpower132: PFS and Safety Results with 1L Atezolizumab plus Carboplatin/Cisplatin plus Pemetrexed in Stage IV Non-Squamous NSCLC
V. Papadimitrakopoulou et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Fernanda G. Herrera et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
Caroline Boudousquie et al.
IMMUNOLOGY (2017)
Wnt/beta-catenin pathway: modulating anticancer immune response
Sachin Gopalkrishna Pai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Jingjing Zhu et al.
NATURE COMMUNICATIONS (2017)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One
Journal for ImmunoTherapy of Cancer (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts Abstracts
[Anonymous]
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT
Quincey LaPlant et al.
PRACTICAL RADIATION ONCOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Next-generation anti-CTLA-4 antibodies
Alan J. Korman et al.
CANCER RESEARCH (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients
C. S. Horjus Talabur Horje et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Clinical and biological effects of demethylating agents on solid tumours - A systematic review
J. F. Linnekamp et al.
CANCER TREATMENT REVIEWS (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J. M. Kim et al.
ANNALS OF ONCOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Chester Lai et al.
CLINICAL CANCER RESEARCH (2016)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
J. Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment
R. Bryan Bell et al.
ORAL ONCOLOGY (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
Michal Bassani-Sternberg et al.
NATURE COMMUNICATIONS (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination
Anke Redeker et al.
FRONTIERS IN IMMUNOLOGY (2016)
Efficacy analysis of MASTERKEY-265 phase lb study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Innate Immune Recognition of Cancer
Seng-Ryong Woo et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Z. Sun et al.
CANCER RESEARCH (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
Peter Johnson et al.
CLINICAL CANCER RESEARCH (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer
Benjamin Weixler et al.
ONCOTARGET (2015)
TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner
Kevin C. Soares et al.
ONCOTARGET (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
OX40-and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence
Sarah L. Buchan et al.
JOURNAL OF IMMUNOLOGY (2015)
Treatment with 5-Aza-2′-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
Agnes S. Klar et al.
PLOS ONE (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Lidia Robert et al.
CLINICAL CANCER RESEARCH (2014)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Heterogeneity in immune responses: from populations to single cells
Rahul Satija et al.
TRENDS IN IMMUNOLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
Antonio M. Grimaldi et al.
ONCOIMMUNOLOGY (2014)
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Encouse B. Golden et al.
ONCOIMMUNOLOGY (2014)
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
Nadeem A. Sheikh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Current status of interleukin-10 and regulatory T-cells in cancer
Kristen L. Dennis et al.
CURRENT OPINION IN ONCOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms
Stephanie Demoulin et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun et al.
SCIENCE (2013)
Molecular insights for optimizing T cell receptor specificity against cancer
Michael Hebeisen et al.
FRONTIERS IN IMMUNOLOGY (2013)
Structure-based, rational design of T cell receptors
V. Zoete et al.
FRONTIERS IN IMMUNOLOGY (2013)
TGF-β signalling and its role in cancer progression and metastasis
Yvette Drabsch et al.
CANCER AND METASTASIS REVIEWS (2012)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Tumor-Induced CD8+T-Cell Dysfunction in Lung Cancer Patients
Heriberto Prado-Garcia et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness
Melita Irving et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Peter A. Jones
NATURE REVIEWS GENETICS (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
A Critical Role for Dendritic Cells in the Formation of Lymphatic Vessels within Tertiary Lymphoid Structures
Luciana R. Muniz et al.
JOURNAL OF IMMUNOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression
Li Yang et al.
TRENDS IN IMMUNOLOGY (2010)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis
M. Obeid et al.
CELL DEATH AND DIFFERENTIATION (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative
Karl S. Peggs et al.
CANCER CELL (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
High-mobility group box 1 protein (HMGB): Nuclear weapon in the immune arsenal
MT Lotze et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Epigenetics in human disease and prospects for epigenetic therapy
G Egger et al.
NATURE (2004)
Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium
JS Yu et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Sequential 5-aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1
TS Weiser et al.
JOURNAL OF IMMUNOTHERAPY (2001)
分享论文
